CARLSBAD, Calif. — When patients with vitiligo see Jessica Shiu, MD, PhD, for the first time, some mention that prior healthcare providers have told them that vitiligo is merely a cosmetic issue — ...
AbbVie has submitted applications to the FDA and EMA for new indications for upadacitinib (RINVOQ 15-mg) for the treatment of adult and adolescent patients living with non-segmental vitiligo (NSV), ...
Studies evaluating the oral JAK inhibitor in adults and adolescents with non-segmental vitiligo are submitted for approval of the expanded indication.
ITHACA, NY (WBNG) -- Researchers at Cornell University have made progress on treatment for vitiligo, a skin condition and autoimmune disorder that causes white patches to appear on the skin. Associate ...
AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ® ...
Think about a world where a light is restoring your skin’s lost color. Red light therapy lamp is becoming popular for skin pigmentation treatment among people with vitiligo. The common skin condition, ...
AbbVie has submitted applications for a new indication for upadacitinib (RINVOQ) for the treatment of patients living with ...
Favorable outcomes were observed among patients with vitiligo who received systemic Janus kinase inhibitors, with tofacitinib associated with the highest rate of complete resolution. Tofacitinib may ...
AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company ...
Since the Bronze Age, humans have recorded cases of vitiligo -- and attempted to cure it. "3,400 years ago, ancient Indian texts called the Vedas actually wrote about vitiligo specifically and ...
Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo [1,2] ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results